RianCorp is an Australia-headquartered company that focuses on medical laser products for healthcare applications in the field of Low Level Laser Therapy ("LLLT"). RianCorp is the only company in the world to have completed randomized, double-blind clinical trial testing of the effects of LLLT on Lymphedema. (read more)
RianCorp’s cornerstone LTU-904 infra-red low level laser therapy unit is a hand-held device that operates at a wavelength of 904 nanometers. The low-level laser beam penetrates deep into skin tissue where it is absorbed by cells and converted into energy that influences the course of metabolic processes. The laser affected, re-energized cells help to break up fibrotic tissue, reduce pain, inflammation and scar formation and help increase capillary blood vessel formation.
The LTU-904 low-level laser is the only laser to receive FDA clearance for treatment of post mastectomy arm Lymphedema. It is safe and easy to use, and as a Class 1 laser, there are no eye-safety requirements and it will not burn or raise skin temperatures. Use of the LTU-904 low-level laser may be combined with Manual Lymph Drainage ("MLD") and short stretch compression bandaging as part of an overall Lymphedema treatment regimen.